SCHEMBL2179580

SCHEMBL2179580

CCOC(=O)N[C@@H]1CCN(C(c2ccccc2)C(C)C)C[C@H]1O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSK P43235 1/20 0.42
ALDH1A1 P00352 3/20 0.41
KDM4E B2RXH2 2/20 0.41
HPGD P15428 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
TSHR P16473 2/20 0.40
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
CHRM1 P11229 2/20 0.38
NPY2R P49146 1/20 0.38
CACNA1A O00555 1/20 0.37
CACNA2D1 P54289 1/20 0.37
CACNB1 Q02641 1/20 0.37
GAA P10253 1/20 0.37
SLC6A2 P23975 1/20 0.37
SLC6A4 P31645 1/20 0.37
SLC6A3 Q01959 1/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
HTT P42858 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2179575 1.00 CTSK (0.42) CTSKALDH1A1KDM4EHPGDSMN1; SMN2
SCHEMBL2179573 1.00 CTSK (0.42) CTSKALDH1A1KDM4EHPGDSMN1; SMN2
SCHEMBL2179080 0.89 CTSK (0.43) CTSKALDH1A1KDM4EHPGDSMN1; SMN2
SCHEMBL2179078 0.89 CTSK (0.43) CTSKALDH1A1KDM4EHPGDSMN1; SMN2
SCHEMBL2179084 0.89 CTSK (0.43) CTSKALDH1A1KDM4EHPGDSMN1; SMN2
SCHEMBL2177199 0.89 CTSK (0.40) CTSKALDH1A1TSHRMEN1KMT2A
SCHEMBL2177191 0.89 CTSK (0.40) CTSKALDH1A1TSHRMEN1KMT2A
SCHEMBL2177193 0.89 CTSK (0.40) CTSKALDH1A1TSHRMEN1KMT2A
SCHEMBL2178076 0.87 CHRNB2 (0.41) CTSKALDH1A1HTT
SCHEMBL2178078 0.87 CHRNB2 (0.41) CTSKALDH1A1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2351738-A1 PROCESS FOR PRODUCING 1-SUBSTITUTED TRANS-4-(SUBSTITUTED AMINO)PIPERIDIN-3-OL Sumitomo Chemical Company, Limited (JP) 2011-08-03 EP disclosed
US-20110172431-A1 PROCESS FOR PRODUCING 1-SUBSTITUTED TRANS-4-(SUBSTITUTED AMINO) PIPERIDIN-3-OL SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-07-14 US disclosed
US-20110166357-A1 METHOD FOR PRODUCING N-SUBSTITUTED-TRANS-4-AZIDOPIPERIDINE-3-OL SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-07-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110166357-A1 METHOD FOR PRODUCING N-SUBSTITUTED-TRANS-4-AZIDOPIPERIDINE-3-OL RPS27L, OSGEP, RPLP1 CTSK 1604/4885ALDH1A1 264/4885KDM4E 3998/4885
US-20110172431-A1 PROCESS FOR PRODUCING 1-SUBSTITUTED TRANS-4-(SUBSTITUTED AMINO) PIPERIDIN-3-OL TEAD4, TEAD3, TEAD2 CTSK 3003/4885ALDH1A1 93/4885KDM4E 1125/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.